Formycon AG (FSE: FYB, Prime Standard) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) have announced a strategic manufacturing partnership for biosimilars. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its biologics facility in Bangalore, India. The collaboration aims to combine Formycon’s biosimilar development expertise with OneSource’s end-to-end biologics manufacturing capabilities to support Formycon’s biosimilar programs for global markets.
Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, stated: “Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.”
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: “We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics.”
The partnership reflects a shared commitment to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model – one that OneSource is specifically positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
This news matters because biosimilars are critical to expanding patient access to life-saving biologic therapies while reducing healthcare costs. With global biosimilar sales currently around $21 billion and projected to rise to over $74 billion by 2030, efficient manufacturing partnerships are essential to meet growing demand. The collaboration leverages India’s cost advantages and regulatory expertise, potentially lowering drug prices and improving access in emerging markets. Formycon’s FYB4Growth strategy, which includes geographic diversification into regions such as MENA, APAC, and Latin America, will benefit from OneSource’s manufacturing footprint. For the industry, this partnership highlights the trend of Western developers teaming with Indian CDMOs to optimize supply chains and accelerate time-to-market for biosimilars.
